Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
Howard Berman, Ph.D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024.Mark H. Pavao, a senior pharma and biotech executive, joins the Board as an independent director. HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that founder Howard Berman, Ph.D., has stepped down as Executive Chairman and as a member of the Board, and that Mark H. Pavao has been appointed to the Board as an independent director.Dr. Berman became Executive Chairman in November 2024 as part of a planned CEO transition that established Arun Swaminathan, Ph.D., as the Company’s Chief Executive Officer. Dr. Berman’s departure from the Executive Chairman role was a contemplated next step in that pr
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics (COYA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=COYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" MarketBeat
- Coya Therapeutics (COYA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
- Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALSBusiness Wire
- ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COOBusiness Wire
- Coya Therapeutics (COYA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
COYA
Earnings
- 3/16/26 - Miss
COYA
Sec Filings
- 4/9/26 - Form 4
- 4/9/26 - Form 3
- 4/2/26 - Form 8-K
- COYA's page on the SEC website